Antigen Peptide Transporter 1 (TAP1) Promotes Resistance to MEK Inhibitors in Pancreatic Cancers

Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors show limited benefit in Kirsten rat sarcoma (KRAS) mutant pancreatic cancer due to drug resistance. To identify mechanisms of resistance to MEK inhibitor (MEKi), we employed a differential expression analysis of MEKi-sensitive versus ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Boya, Feng, Yu, Hou, Qiaoyun, Fu, Yan, Luo, Yongzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266799/
https://www.ncbi.nlm.nih.gov/pubmed/35806187
http://dx.doi.org/10.3390/ijms23137168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266799/
https://www.ncbi.nlm.nih.gov/pubmed/35806187
http://dx.doi.org/10.3390/ijms23137168

Ejemplares similares